Contrasting Sema4 (SMFR) & Its Peers

Sema4 (NASDAQ:SMFRGet Rating) is one of 33 publicly-traded companies in the “Health services” industry, but how does it contrast to its peers? We will compare Sema4 to related businesses based on the strength of its profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Earnings & Valuation

This table compares Sema4 and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Sema4 $212.20 million -$245.39 million -0.57
Sema4 Competitors $1.36 billion -$98.47 million 29.16

Sema4’s peers have higher revenue and earnings than Sema4. Sema4 is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Sema4 and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sema4 -121.31% -53.31% -36.04%
Sema4 Competitors -325.87% -481.74% -38.64%

Analyst Ratings

This is a summary of current ratings and price targets for Sema4 and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sema4 0 1 4 0 2.80
Sema4 Competitors 7 130 274 0 2.65

Sema4 currently has a consensus target price of $3.08, suggesting a potential upside of 482.09%. As a group, “Health services” companies have a potential upside of 117.59%. Given Sema4’s stronger consensus rating and higher probable upside, analysts plainly believe Sema4 is more favorable than its peers.

Institutional & Insider Ownership

48.6% of shares of all “Health services” companies are owned by institutional investors. 21.6% of shares of all “Health services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Sema4 has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Sema4’s peers have a beta of 1.48, meaning that their average share price is 48% more volatile than the S&P 500.


Sema4 beats its peers on 7 of the 12 factors compared.

About Sema4

(Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.

Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with's FREE daily email newsletter.